Sofinnova group cuts Abivax (ABVX) stake to 3.33M shares, 7.7% votes

Rhea-AI Filing Summary

Abivax S.A. shareholder Sofinnova Crossover I SLP and affiliated reporting persons update their ownership after selling American depositary shares in the market. On January 12 and 13, 2026, Sofinnova Crossover I SLP sold multiple blocks of Abivax ADSs in open‑market transactions at weighted average prices ranging from $118.27 to $141.26 per ADS, plus a separate trade of 100 ADS at $142.00 per ADS.

As of January 14, 2026, Sofinnova Crossover I SLP holds 3,334,739 Ordinary Shares, representing about 4.3% of Abivax’s 78,398,795 Ordinary Shares outstanding as of November 30, 2025. These shares carry 6,399,478 voting rights, or 7.7% of the 82,688,932 voting rights outstanding. The management company Sofinnova Partners SAS and investment committee members may be deemed to share voting and investment control, although the individuals disclaim beneficial ownership except for their pecuniary interests.

Insights

Equity ownership and governance analyst

Large Abivax holder trims its position but remains a significant voting shareholder.

Sofinnova Crossover I SLP reports open‑market sales of Abivax American depositary shares on January 12, 2026 and January 13, 2026. The trades occurred in multiple blocks, with weighted average prices between $118.27 and $141.26 per ADS, plus a 100‑ADS sale at $142.00. This reflects active portfolio management by a financial sponsor rather than a change disclosed in Abivax’s operations.

After these transactions, Sofinnova Crossover I SLP directly holds 3,334,739 Ordinary Shares, equal to about 4.3% of the 78,398,795 Ordinary Shares outstanding as of November 30, 2025. These shares correspond to 6,399,478 voting rights, or 7.7% of the 82,688,932 voting rights outstanding, keeping Sofinnova a notable voting bloc. The filing states the shares were acquired for investment purposes and that the reporting persons may buy or sell further securities as permitted by law.

The management company Sofinnova Partners SAS and committee members Antoine Papiernik, Cedric Moreau, Kinam Hong, Joseph Anderson, and Jacques Theurillat may be deemed to share voting and investment control over Sofinnova Crossover I SLP’s holdings. The individuals disclaim beneficial ownership beyond their pecuniary interests. Future ownership levels will depend on any additional transactions the group may choose to undertake, which would be reflected in subsequent beneficial ownership reports.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 4)

Abivax S.A.

(Name of Issuer)

Ordinary Shares, par value EUR0.01 per share

(Title of Class of Securities)

00370M103

(CUSIP Number)

Armance Bordes
7-11, boulevard Haussmann,
Paris, I0, 75009
33 1 76 23 41 09

John Partigan Lloyd Spencer
Nixon Peabody LLP, 799 9 Street NW Ste 500
Washington, DC, 20001
202-585-8000

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

01/12/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No. 00370M103

1

Name of reporting person

Sofinnova Crossover I SLP

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

FRANCE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 6,399,478.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 3,334,739.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

6,399,478.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

7.7 %

14

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person:

Note in relation to Items 7 and 8: Sofinnova Partners SAS, a French corporation ("SP SAS"), the management company of Sofinnova Crossover I SLP ("SC"), may be deemed to have sole voting power, and Antoine Papiernik ("Papiernik"), Cedric Moreau ("Moreau"), Kinam Hong ("Hong"), Joseph Anderson ("Anderson") and Jacques Theurillat ("Theurillat"), the members of the investment committee of SC, may be deemed to have shared power to vote these shares. Note in relation to Items 9 and 10: SP SAS, the management company of SC, may be deemed to have sole power to dispose of these shares, and Papiernik, Moreau, Hong, Anderson and Theurillat, the members of the investment committee of SC, may be deemed to have shared power to dispose of these shares. Note in relation to Items 8, 10, 11 and 13: The Reporting Person beneficially owns 3,334,739 Ordinary Shares (including ordinary shares represented by American depositary shares) and has 6,399,478 voting rights related to such shares. The aggregate amount beneficially owned and percent of class reported above are based on the Reporting Person's voting rights and the 82,688,932 voting rights outstanding as of November 30, 2025.

SCHEDULE 13D

CUSIP No. 00370M103

1

Name of reporting person

Sofinnova Partners SAS

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

FRANCE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 6,399,478.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 3,334,739.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

6,399,478.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

7.7 %

14

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person:

Note in relation to Items 7 and 8: SP SAS, the management company of SC, may be deemed to have sole voting power, and Papiernik, Moreau, Hong, Anderson and Theurillat, the members of the investment committee of SC, may be deemed to have shared power to vote these shares. Note in relation to Items 9 and 10: SP SAS, the management company of SC, may be deemed to have sole power to dispose of these shares, and Papiernik, Moreau, Hong, Anderson and Theurillat, the members of the investment committee of SC, may be deemed to have shared power to dispose of these shares. Note in relation to Items 8, 10, 11 and 13: The Reporting Person beneficially owns 3,334,739 Ordinary Shares (including ordinary shares represented by American depositary shares) and has 6,399,478 voting rights related to such shares. The aggregate amount beneficially owned and percent of class reported above are based on the Reporting Person's voting rights and the 82,688,932 voting rights outstanding as of November 30, 2025.

SCHEDULE 13D

CUSIP No. 00370M103

1

Name of reporting person

Antoine Papiernik

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

FRANCE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 6,399,478.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 3,334,739.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

6,399,478.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

7.7 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

Note to Items 7 and 8: SP SAS, the management company of SC, may be deemed to have sole voting power, and Papiernik, a member of the investment committee of SC, may be deemed to have shared power to vote these shares. Note to Items 9 and 10: SP SAS, the management company of SC, may be deemed to have sole power to dispose of these shares, and Papiernik, a member of the investment committee of SC, may be deemed to have shared power to dispose of these shares. Note in relation to Items 8, 10, 11 and 13: The Reporting Person beneficially owns 3,334,739 Ordinary Shares (including ordinary shares represented by American depositary shares) and has 6,399,478 voting rights related to such shares. The aggregate amount beneficially owned and percent of class reported above are based on the Reporting Person's voting rights and the 82,688,932 voting rights outstanding as of November 30, 2025.

SCHEDULE 13D

CUSIP No. 00370M103

1

Name of reporting person

Cedric Moreau

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

FRANCE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 6,399,478.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 3,334,739.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

6,399,478.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

7.7 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

Note to Items 7 and 8: SP SAS, the management company of SC, may be deemed to have sole voting power, and Moreau, a member of the investment committee of SC, may be deemed to have shared power to vote these shares. Note to Items 9 and 10: SP SAS, the management company of SC, may be deemed to have sole power to dispose of these shares, and Moreau, a member of the investment committee of SC, may be deemed to have shared power to dispose of these shares. Note in relation to Items 8, 10, 11 and 13: The Reporting Person beneficially owns 3,334,739 Ordinary Shares (including ordinary shares represented by American depositary shares) and has 6,399,478 voting rights related to such shares. The aggregate amount beneficially owned and percent of class reported above are based on the Reporting Person's voting rights and the 82,688,932 voting rights outstanding as of November 30, 2025.

SCHEDULE 13D

CUSIP No. 00370M103

1

Name of reporting person

Kinam Hong

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 6,399,478.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 3,334,739.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

6,399,478.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

7.7 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

Note to Items 7 and 8: SP SAS, the management company of SC, may be deemed to have sole voting power, and Hong, a member of the investment committee of SC, may be deemed to have shared power to vote these shares. Note to Items 9 and 10: SP SAS, the management company of SC, may be deemed to have sole power to dispose of these shares, and Hong, a member of the investment committee of SC, may be deemed to have shared power to dispose of these shares. Note in relation to Items 8, 10, 11 and 13: The Reporting Person beneficially owns 3,334,739 Ordinary Shares (including ordinary shares represented by American depositary shares) and has 6,399,478 voting rights related to such shares. The aggregate amount beneficially owned and percent of class reported above are based on the Reporting Person's voting rights and the 82,688,932 voting rights outstanding as of November 30, 2025.

SCHEDULE 13D

CUSIP No. 00370M103

1

Name of reporting person

Joseph Anderson

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED KINGDOM

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 6,399,478.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 3,334,739.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

6,399,478.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

7.7 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

Note to Items 7 and 8: SP SAS, the management company of SC, may be deemed to have sole voting power, and Anderson, a member of the investment committee of SC, may be deemed to have shared power to vote these shares. Note to Items 9 and 10: SP SAS, the management company of SC, may be deemed to have sole power to dispose of these shares, and Anderson, a member of the investment committee of SC, may be deemed to have shared power to dispose of these shares. Note in relation to Items 8, 10, 11 and 13: The Reporting Person beneficially owns 3,334,739 Ordinary Shares (including ordinary shares represented by American depositary shares) and has 6,399,478 voting rights related to such shares. The aggregate amount beneficially owned and percent of class reported above are based on the Reporting Person's voting rights and the 82,688,932 voting rights outstanding as of November 30, 2025.

SCHEDULE 13D

CUSIP No. 00370M103

1

Name of reporting person

Jacques Theurillat

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

SWITZERLAND

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 6,399,478.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 3,334,739.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

6,399,478.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

7.7 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

Note to Items 7 and 8: SP SAS, the management company of SC, may be deemed to have sole voting power, and Theurillat, a member of the investment committee of SC, may be deemed to have shared power to vote these shares. Note to Items 9 and 10: SP SAS, the management company of SC, may be deemed to have sole power to dispose of these shares, and Theurillat, a member of the investment committee of SC, may be deemed to have shared power to dispose of these shares. Note in relation to Items 8, 10, 11 and 13: The Reporting Person beneficially owns 3,334,739 Ordinary Shares (including ordinary shares represented by American depositary shares) and has 6,399,478 voting rights related to such shares. The aggregate amount beneficially owned and percent of class reported above are based on the Reporting Person's voting rights and the 82,688,932 voting rights outstanding as of November 30, 2025.

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Ordinary Shares, par value EUR0.01 per share
(b)	Name of Issuer: Abivax S.A.
(c)	Address of Issuer's Principal Executive Offices: 7-11, boulevard Haussmann, Paris, FRANCE , 75009.
Item 1 Comment: Introductory Statement: This Amendment No. 4 (this "Amendment"), being filed by Sofinnova Crossover I SLP ("SC"), Sofinnova Partners SAS, a French corporation ("SP SAS"), Antoine Papiernik ("Papiernik"), Cedric Moreau ("Moreau"), Kinam Hong ("Hong"), Joseph Anderson ("Anderson") and Jacques Theurillat ("Theurillat") the members of the investment committee of SC (collectively, the "Listed Persons" and together with SC and SP SAS, the "Reporting Persons"), amends and supplements the Schedule 13D filed with the Securities and Exchange Commission (the "SEC") on October 30, 2023, as amended by Amendment No. 1, filed with the SEC on February 14, 2025, as further amended by Amendment No. 2, filed with the SEC on July 31, 2025, and as further amended by Amendment No. 3, filed with the SEC on October 30, 2025 (collectively, as amended, the "Schedule 13D"). This Schedule 13D relates to the Ordinary Shares, par value EUR0.01 per share (the "Ordinary Shares"), including ordinary shares represented by American Depositary Shares ("ADS"), of Abivax SA, a societe anonyme incorporated under the laws of the French Republic (the "Issuer"). Except as specifically provided herein, this Amendment No. 4 does not modify any of the information previously reported in the Schedule 13D. Capitalized terms used herein shall have the meanings ascribed to them in the Schedule 13D.
Item 2.	Identity and Background
(d)	During the last five years, none of the Reporting Persons has been convicted in any criminal proceeding (excluding traffic violations or similar misdemeanors).
(e)	During the last five years, none of the Reporting Persons has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
Item 4.	Purpose of Transaction
	Item 4 of the Schedule 13D is hereby amended and supplemented as follows: SC sold the amounts of ADS on the date and at the prices set forth below in open market transactions. All daily sales of the shares were sold in multiple transactions at varying prices. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this Schedule 13D. January 12, 2026: - 130,984 ADSs at a weighted average price of $118.27 per share (multiple transactions at prices ranging from $118.00 to $118.89, inclusive); - 201,997 ADSs at a weighted average price of $119.33 per share (multiple transactions at prices ranging from $119.00 to $119.99, inclusive); - 353,987 ADSs at a weighted average price of $120.37 per share (multiple transactions at prices ranging from $120.00 to $120.99, inclusive); - 58,126 ADSs at a weighted average price of $121.47 per share (multiple transactions at prices ranging from $121.00 to $121.99, inclusive); - 40,364 ADSs at a weighted average price of $122.24 per share (multiple transactions at prices ranging from $122.00 to $122.94, inclusive); - 6,609 ADSs at a weighted average price of $123.13 per share (multiple transactions at prices ranging from $123.01 to $123.23, inclusive); - 18,226 ADSs at a weighted average price of $125.37 per share (multiple transactions at prices ranging from $125.05 to $125.99, inclusive); - 31,780 ADSs at a weighted average price of $126.32 per share (multiple transactions at prices ranging from $126.00 to $126.96, inclusive); - 3,434 ADSs at a weighted average price of $127.09 per share (multiple transactions at prices ranging from $127.01 to $127.36, inclusive); - 8,054 ADSs at a weighted average price of $137.48 per share (multiple transactions at prices ranging from $137.00 to $137.97, inclusive); - 41,103 ADSs at a weighted average price of $138.45 per share (multiple transactions at prices ranging from $138.00 to $138.99, inclusive); - 30,131 ADSs at a weighted average price of $139.48 per share (multiple transactions at prices ranging from $139.00 to $139.99, inclusive); - 21,963 ADSs at a weighted average price of $140.26 per share (multiple transactions at prices ranging from $140.00 to $140.86, inclusive); - 3,142 ADSs at a weighted average price of $141.26 per share (multiple transactions at prices ranging from $141.00 to $141.89, inclusive); and - 100 ADS at $142.00 per share. January 13, 2026: - 17,500 ADSs at a weighted average price of $119.51 per share (multiple transactions at prices ranging from $119.16 to $120.02, inclusive); - 10,473 ADSs at a weighted average price of $120.30 per share (multiple transactions at prices ranging from $120.21 to $120.64, inclusive); - 18,405 ADSs at a weighted average price of $122.24 per share (multiple transactions at prices ranging from $122.00 to $122.94, inclusive); and - 3,622 ADSs at a weighted average price of $123.04 per share (multiple transactions at prices ranging from $123.00 to $123.33, inclusive). All of the Ordinary Shares that are held of record by the Reporting Persons as reported herein were acquired for investment purposes. The Reporting Persons retain the right to change their investment intent, from time to time to acquire additional Ordinary Shares or other securities of the Issuer, or to sell or otherwise dispose of all or part of the Ordinary Shares or other securities of the Issuer, if any, beneficially owned by them, in any manner permitted by law. The Reporting Persons may engage from time to time in ordinary course transactions with financial institutions with respect to the securities described herein. Except as set forth above, none of the Reporting Persons currently has any plans or proposals which would be related to or would result in any of the matters described in Items 4(a)-(j) of the Instructions to Schedule 13D. However, as part of the ongoing evaluation of investment and investment alternatives, the Reporting Persons may consider such matters and, subject to applicable law, may formulate a plan with respect to such matters, and, from time to time, may hold discussions with or make formal proposals to management or the board of directors of the Issuer or other third parties regarding such matters.
Item 5.	Interest in Securities of the Issuer
(a)	Item 5(a) of the Schedule 13D is hereby amended and supplemented as follows: As of January 14, 2026, SC held directly 3,334,739 Ordinary Shares representing approximately 4.3% of the Issuer's outstanding Ordinary Shares and 6,399,478 voting rights representing approximately 7.7% of the Issuer's outstanding voting rights. None of the other Reporting Persons hold any Ordinary Shares or ADSs directly. SP SAS is the management company of SC and may be deemed to have shared voting and investment control over the Ordinary Shares and ADSs held by SC. Each of Antoine Papiernik, Cedric Moreau, Kinam Hong, Joseph Anderson and Jacques Theurillat are the members of the investment committee of SC and may be deemed to have shared voting and investment control over the Ordinary Shares and ADSs held by SC. Each of such individuals disclaims beneficial ownership of such Ordinary Shares and ADSs except to the extent of their pecuniary interest therein. The ownership percentages are based upon 78,398,795 of the Issuer's Ordinary Shares outstanding as of November 30, 2025. The voting percentages are based upon 82,688,932 voting rights outstanding as of November 30, 2025.
(b)	Item 5(b) of the Schedule 13D is hereby amended and supplemented as follows: See the information contained on the cover pages of this Amendment, which is incorporated herein by reference.
(c)	Item 5(c) of the Schedule 13D is hereby amended and supplemented as follows: Except as disclosed herein, there have been no other reportable transactions with respect to the Ordinary Shares or ADSs of the Issuer within the last 60 days by the Reporting Persons.
Item 7.	Material to be Filed as Exhibits.
	EX 99.1 - Agreement regarding filing of joint Schedule 13D (incorporated by reference from Exhibit 99.1 to Schedule 13D filed by the Reporting Persons on October 30, 2023)

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Sofinnova Crossover I SLP

Signature:	/s/ Antoine Papiernik
Name/Title:	Managing Partner
Date:	01/14/2026

Sofinnova Partners SAS

Signature:	/s/ Antoine Papiernik
Name/Title:	Managing Partner
Date:	01/14/2026

Antoine Papiernik

Signature:	/s/ Antoine Papiernik
Name/Title:	Antoine Papiernik
Date:	01/14/2026

Cedric Moreau

Signature:	/s/ Cedric Moreau
Name/Title:	Cedric Moreau
Date:	01/14/2026

Kinam Hong

Signature:	/s/ Kinam Hong
Name/Title:	Kinam Hong
Date:	01/14/2026

Joseph Anderson

Signature:	/s/ Joseph Anderson
Name/Title:	Joseph Anderson
Date:	01/14/2026

Jacques Theurillat

Signature:	/s/ Jacques Theurillat
Name/Title:	Jacques Theurillat
Date:	01/14/2026

FAQ

What ownership stake does Sofinnova currently report in Abivax (ABVX)?

As of January 14, 2026, Sofinnova Crossover I SLP reports holding 3,334,739 Ordinary Shares of Abivax, representing about 4.3% of the 78,398,795 Ordinary Shares outstanding as of November 30, 2025, and 6,399,478 voting rights, or 7.7% of the 82,688,932 voting rights outstanding.

What transactions triggered this Schedule 13D/A amendment for Abivax (ABVX)?

The amendment reflects that Sofinnova Crossover I SLP sold multiple blocks of Abivax American depositary shares in open‑market transactions on January 12 and 13, 2026, at weighted average prices between $118.27 and $141.26 per ADS, plus a 100‑ADS sale at $142.00 per ADS.

Who are the reporting persons in this Abivax (ABVX) Schedule 13D/A filing?

The reporting persons are Sofinnova Crossover I SLP, its management company Sofinnova Partners SAS, and investment committee members Antoine Papiernik, Cedric Moreau, Kinam Hong, Joseph Anderson, and Jacques Theurillat.

Do the individual Sofinnova committee members directly own Abivax (ABVX) shares?

The filing states that none of the individual reporting persons directly holds Ordinary Shares or ADSs. Their reported interest arises through Sofinnova Crossover I SLP, and each individual disclaims beneficial ownership except to the extent of any pecuniary interest.

How much voting influence does Sofinnova have in Abivax (ABVX)?

Sofinnova Crossover I SLP’s holdings carry 6,399,478 voting rights, which equals about 7.7% of Abivax’s 82,688,932 voting rights outstanding as of November 30, 2025, giving the group a significant minority voting position.

What is Sofinnova’s stated purpose for holding Abivax (ABVX) shares?

The filing states that all Ordinary Shares held of record by the reporting persons were acquired for investment purposes. They reserve the right to buy additional securities or sell or otherwise dispose of existing holdings in any manner permitted by law.